Literature DB >> 12805549

Transcription start regions in the human genome are favored targets for MLV integration.

Xiaolin Wu1, Yuan Li, Bruce Crise, Shawn M Burgess.   

Abstract

Factors contributing to retroviral integration have been intractable because past studies have not precisely located genomic sites of proviruses in sufficient numbers for significant analysis. In this study, 903 murine leukemia virus (MLV) and 379 human immunodeficiency virus-1 (HIV-1) integrations in the human genome were mapped. The data showed that MLV preferred integration near the start of transcriptional units (either upstream or downstream) whereas HIV-1 preferred integration anywhere in the transcriptional unit but not upstream of the transcriptional start. Defining different integration site preferences for retroviruses will have important ramifications for gene therapy and may aid in our understanding of the factors directing the integration process.

Entities:  

Mesh:

Year:  2003        PMID: 12805549     DOI: 10.1126/science.1083413

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  551 in total

1.  Gene therapy for canine leukocyte adhesion deficiency with lentiviral vectors using the murine stem cell virus and human phosphoglycerate kinase promoters.

Authors:  Michael J Hunter; Huifen Zhao; Laura M Tuschong; Thomas R Bauer; Tanya H Burkholder; Derek A Persons; Dennis D Hickstein
Journal:  Hum Gene Ther       Date:  2011-04-11       Impact factor: 5.695

2.  Gene therapy: two steps forward, one step back.

Authors:  Josephine Johnston; Francoise Baylis
Journal:  CMAJ       Date:  2004-06-08       Impact factor: 8.262

3.  Mutator genes for suppression of gross chromosomal rearrangements identified by a genome-wide screening in Saccharomyces cerevisiae.

Authors:  Stephanie Smith; Ji-Young Hwang; Soma Banerjee; Anju Majeed; Amitabha Gupta; Kyungjaem Myung
Journal:  Proc Natl Acad Sci U S A       Date:  2004-06-07       Impact factor: 11.205

4.  Resting CD4+ T cells from human immunodeficiency virus type 1 (HIV-1)-infected individuals carry integrated HIV-1 genomes within actively transcribed host genes.

Authors:  Yefei Han; Kara Lassen; Daphne Monie; Ahmad R Sedaghat; Shino Shimoji; Xiao Liu; Theodore C Pierson; Joseph B Margolick; Robert F Siliciano; Janet D Siliciano
Journal:  J Virol       Date:  2004-06       Impact factor: 5.103

5.  High-level beta-globin expression and preferred intragenic integration after lentiviral transduction of human cord blood stem cells.

Authors:  Suzan Imren; Mary E Fabry; Karen A Westerman; Robert Pawliuk; Patrick Tang; Patricia M Rosten; Ronald L Nagel; Philippe Leboulch; Connie J Eaves; R Keith Humphries
Journal:  J Clin Invest       Date:  2004-10       Impact factor: 14.808

Review 6.  A realistic chance for gene therapy in the near future.

Authors:  Stefan Worgall
Journal:  Pediatr Nephrol       Date:  2004-11-10       Impact factor: 3.714

Review 7.  Safe harbours for the integration of new DNA in the human genome.

Authors:  Michel Sadelain; Eirini P Papapetrou; Frederic D Bushman
Journal:  Nat Rev Cancer       Date:  2011-12-01       Impact factor: 60.716

8.  Host factors that affect Ty3 retrotransposition in Saccharomyces cerevisiae.

Authors:  Michael Aye; Becky Irwin; Nadejda Beliakova-Bethell; Eric Chen; Jennifer Garrus; Suzanne Sandmeyer
Journal:  Genetics       Date:  2004-11       Impact factor: 4.562

9.  Differential effects of human immunodeficiency virus type 1 capsid and cellular factors nucleoporin 153 and LEDGF/p75 on the efficiency and specificity of viral DNA integration.

Authors:  Yasuhiro Koh; Xiaolin Wu; Andrea L Ferris; Kenneth A Matreyek; Steven J Smith; KyeongEun Lee; Vineet N KewalRamani; Stephen H Hughes; Alan Engelman
Journal:  J Virol       Date:  2012-10-24       Impact factor: 5.103

10.  A resurrected mammalian hAT transposable element and a closely related insect element are highly active in human cell culture.

Authors:  Xianghong Li; Hosam Ewis; Robert H Hice; Nirav Malani; Nicole Parker; Liqin Zhou; Cédric Feschotte; Frederic D Bushman; Peter W Atkinson; Nancy L Craig
Journal:  Proc Natl Acad Sci U S A       Date:  2012-10-22       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.